- Home
- UPC vs BCAB Comparison
UPC vs BCAB Comparison
Compare UPC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPC
- BCAB
- Stock Information
- Founded
- UPC 1998
- BCAB 2007
- Country
- UPC China
- BCAB United States
- Employees
- UPC N/A
- BCAB N/A
- Industry
- UPC Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- UPC Health Care
- BCAB Health Care
- Exchange
- UPC Nasdaq
- BCAB Nasdaq
- Market Cap
- UPC 76.8M
- BCAB 91.4M
- IPO Year
- UPC 2021
- BCAB 2020
- Fundamental
- Price
- UPC $0.49
- BCAB $1.67
- Analyst Decision
- UPC
- BCAB Strong Buy
- Analyst Count
- UPC 0
- BCAB 3
- Target Price
- UPC N/A
- BCAB $8.67
- AVG Volume (30 Days)
- UPC 4.9M
- BCAB 688.9K
- Earning Date
- UPC 01-01-0001
- BCAB 08-08-2024
- Dividend Yield
- UPC N/A
- BCAB N/A
- EPS Growth
- UPC N/A
- BCAB N/A
- EPS
- UPC N/A
- BCAB N/A
- Revenue
- UPC $32,308,735.00
- BCAB N/A
- Revenue This Year
- UPC N/A
- BCAB N/A
- Revenue Next Year
- UPC N/A
- BCAB N/A
- P/E Ratio
- UPC N/A
- BCAB N/A
- Revenue Growth
- UPC N/A
- BCAB N/A
- 52 Week Low
- UPC $0.38
- BCAB $1.14
- 52 Week High
- UPC $4.32
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- UPC 15.34
- BCAB 50.39
- Support Level
- UPC $0.38
- BCAB $1.72
- Resistance Level
- UPC $3.34
- BCAB $1.92
- Average True Range (ATR)
- UPC 0.45
- BCAB 0.13
- MACD
- UPC -0.28
- BCAB -0.01
- Stochastic Oscillator
- UPC 5.06
- BCAB 37.04
About UPC Universe Pharmaceuticals Inc.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.